莱特综合征中的克拉米迪菌.

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Extracellular ATP hydrolysis in Caco-2 human intestinal cell line.

Biochimica et biophysica acta. Biomembranes·2021

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Fertility Treatment Using Assisted Reproductive Technology During Immune Checkpoint Inhibition: Report of Two Cases.

The oncologist·2026

Reproductive healthcare use before and after infertility diagnosis: a population-based study in South Korea.

BMJ open·2026

Cost-effectiveness of safer conception strategies for HIV-discordant couples in Zimbabwe.

Journal of acquired immune deficiency syndromes (1999)·2026

Late-follicular androgen and estrogen rise associated with clinical pregnancy in IVF/ICSI with granulosa cell studies.

Reproduction & fertility·2026

Innovative treatment approaches for azoospermia: causes, emerging techniques, and future directions.

Molecular biology reports·2026

Effect of patient and partner preconceptional nutraceutical supplementation on the onset of natural pregnancy: a retrospective study.

Revista da Associacao Medica Brasileira (1992)·2026

相关实验视频

莱特综合征中的克拉米迪菌.

相关概念视频

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.

Extracellular ATP hydrolysis in Caco-2 human intestinal cell line.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Fertility Treatment Using Assisted Reproductive Technology During Immune Checkpoint Inhibition: Report of Two Cases.

Reproductive healthcare use before and after infertility diagnosis: a population-based study in South Korea.

Cost-effectiveness of safer conception strategies for HIV-discordant couples in Zimbabwe.

Late-follicular androgen and estrogen rise associated with clinical pregnancy in IVF/ICSI with granulosa cell studies.

Innovative treatment approaches for azoospermia: causes, emerging techniques, and future directions.

Effect of patient and partner preconceptional nutraceutical supplementation on the onset of natural pregnancy: a retrospective study.

相关实验视频

莱特综合征中的克拉米迪菌.

相关概念视频

相关文章